Google
EVAX 株価分析 — Evaxion Biotech AS (Healthcare >> Biotechnology)
EVAX に関するよくある質問
EVAXのPER（株価収益率）は？
Evaxion Biotech AS（EVAX）は現在PER 5.09倍で取引されています。
EVAXのROE（自己資本利益率）は？
Evaxion Biotech ASのROEは-73.90%です。
EVAXの配当利回りは？
Evaxion Biotech ASの配当利回りは0.00%です。
EVAXの品質スコア（Quality Score）は？
当社のAIはEVAXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EVAXは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EVAXはどのセクターに属しますか？
Evaxion Biotech ASはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
EVAX AI Analysis Summary
Our AI summary for EVAX: Evaxion Biotech AS (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 5.09, ROE of -73.90%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.79
Price
-0.03
(-1.06%)
Day Change
|
|
|---|
EVAX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 74 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.79 |
| PBV / Sector |
1.78 / 44,219.29
|
| Earning Per Share | -1.16 |
| PE / Sector |
5.09 / 19.28
GREAT
|
| PEG or PE/Growth / Sector |
-0.09 / 1.23
|
| Average 1M Daily Value |
0.04 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:29 |
| Symbol | EVAX |
| Name | EVAXION BIOTECH AS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 8.34 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23.52 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Dr. Neergaards Vej, Horsholm, Denmark, 2970
Phone: 45 53 53 18 50
Website: https://evaxion.ai
Sector: Healthcare >> Biotechnology
Description: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
